Important Information on Alternative Site Meters from FDA
Some glucose testing meters allow blood sugar testing from alternative sites, such as the upper arm, forearm, base of the thumb, and thigh.
Sampling blood from alternative glucose testing sites may be desirable, but it may have some limitations. Blood in the fingertips show changes in glucose levels more quickly than blood in other parts of the body. This means that alternative site glucose testing results may be different from fingertip test results not because of the meter's ability to test accurately, but because the actual glucose concentration can be different. FDA believes that further research is needed to better understand these differences in test values and their possible impact on the health of people with diabetes.
Glucose concentrations change rapidly after a meal, insulin or exercise. Glucose levels at the alternative site appear to change more slowly than in the fingertips. Because of this concern, FDA has now requested that manufacturers either show their device is not affected by differences between alternative site and fingertip blood samples during times of rapidly changing glucose, or alert users about possible different values at these times.
Recommended labeling precautions include these statements:
- Alternative glucose testing site results may be different than the fingertip when glucose levels are changing rapidly (e.g. after a meal, taking insulin, or during or after exercise).
- Do not test at an alternative glucose testing site, but use samples taken from the fingertip if:
- you think your blood sugar is low
- you are not aware of symptoms when you become hypoglycemic
- the site results do not agree with the way you feel
In October, 2001, FDA held a public meeting to discuss the types of information and labeling needed for glucose measuring devices if the blood sample is taken from alternative glucose testing sites rather than the fingertip. Presenters included manufacturers of blood glucose meters, healthcare providers, people with diabetes, and parents of children with diabetes.
For more information about the panel meeting on alternative site testing, use the following link:
Clinical Chemistry and Clinical Toxicology Devices Panel Meeting Summary for October 29, 2001
Reviewed by Francine Kaufman, MD. 4/08
Health Nut Sandwich Sweet and Sassy Cherry Sauce Lemon and Balsamic Vinaigrette Mixed Berry Smoothie Jeweled Fruit Tart Zesty Hot Holiday Broccoli Dip Cheddar n' Ham Muffins Cold Lemon Broccoli Salad Jamaican Chicken Salad Brown Sugar Pears with Vanilla Yogurt
If you listen closely, you may hear the sound of 25 million Americans with diabetes rejoicing today. In a revolutionary movement, the FDA has given 510(k) approval on Abbott's HbA1C test which is expected to help millions of Americans with Type 1 or 2 diabetes or those at risk. Abbott's ARCHITECT Clinical Chemistry Hemoglobin A1C (HbA1C) test is a dramatic shift in diabetes diagnosis and monitoring. Instead of the HbA1C tests performed at a laboratory and constituted as blood work, the...